Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment

This study has been completed.
Sponsor:
Information provided by:
Arena Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00828932
First received: January 22, 2009
Last updated: July 27, 2009
Last verified: July 2009

January 22, 2009
July 27, 2009
August 2008
December 2008   (final data collection date for primary outcome measure)
The primary objective of this study is to evaluate the pharmacokinetic properties of lorcaserin in subjects with mild or moderate hepatic impairment compared to subjects with normal hepatic function. [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00828932 on ClinicalTrials.gov Archive Site
To evaluate the safety and tolerability of lorcaserin [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment
An Open Label, Single Dose Study of the Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment

The purpose of this study is to evaluate and establish whether lorcaserin dose adjustment is required in patients with mild or moderate hepatic impairment.

Not Provided
Interventional
Phase 1
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Hepatic Impairment
Drug: Lorcaserin
Experimental: Lorcaserin 10mg
Intervention: Drug: Lorcaserin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
24
December 2008
December 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Males or females aged between 18 and 75 years (inclusive)
  2. Able to give signed informed consent
  3. Hepatic function will fall into one of the following categories:

    • One-third of patients will have normal hepatic function (defined as having all of the following parameters within the normal range of the clinical laboratory used for this trial: AST, ALT, alkaline phosphatase, total bilirubin)
    • One-third of patients will have mild impairment (Child-Pugh score 5-6)
    • One-third of patients will have moderate impairment (Child-Pugh score 7-9)
  4. All subjects will have a BMI of 27-45 kg/m2, inclusive.
  5. Eligible male and female patients must agree not to participate in a conception process
  6. Considered to be in stable health in the opinion of the Investigator.

Exclusion Criteria:

  1. Prior participation in any study of lorcaserin.
  2. Clinically significant new illness in the 1 month before screening
  3. Not suitable to participate in the study in the opinion of the Investigator including an existing physical or mental condition that prevents compliance with the protocol
  4. History of any of the following cardiovascular conditions:

    • Myocardial infarction (diagnosed by cardiac enzyme[s] and/or diagnostic ECG), CVA, TIA or RIND within 6 months of screening
    • Cardiac arrhythmia requiring initiation of new medical or surgical treatment within 6 months of screening (stable medical therapy for > 6 months, pacemakers and/or defibrillators implanted > 6 months prior to screening are acceptable)
    • Unstable angina
  5. Surgically implanted portacaval shunts are excluded with the following exception: transjugular intrahepatic portosystemic shunts (TIPS) will be allowed if placed no less than 3 months prior to dosing
  6. Malignancy within 2 years of the screening visit (except basal cell or squamous cell carcinoma with clean surgical margins)
  7. Initiation of a new prescription medication within 1 month prior to screening.
  8. Recent history (within 3 months prior to the screening visit) of alcohol or drug/solvent abuse or a positive screen for drugs of abuse at screening.
  9. Use of SSRI's, SNRI's, and other medications must meet the required washout periods.
  10. Participated in any clinical study with an investigational drug, biologic, or device within 1 month prior to dosing
Both
18 Years to 75 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00828932
APD356-017
No
Christen Anderson, MD, PhD, Arena Pharmaceuticals, INc.
Arena Pharmaceuticals
Not Provided
Investigator: Christen Anderson, MD, PhD Arena Pharmaceuticals
Arena Pharmaceuticals
July 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP